BR112017027677A2 - peptídeo, composto, mólecula de ácido nucleico, vetor, uso de um peptídeo, anticorpo, composição imunogênica, kit, métodos para determinar se um indivíduo tem lma e para produzir uma célula imune e/ou anticorpo, veículo de dispensação de gene, e, célula hospedeira - Google Patents

peptídeo, composto, mólecula de ácido nucleico, vetor, uso de um peptídeo, anticorpo, composição imunogênica, kit, métodos para determinar se um indivíduo tem lma e para produzir uma célula imune e/ou anticorpo, veículo de dispensação de gene, e, célula hospedeira

Info

Publication number
BR112017027677A2
BR112017027677A2 BR112017027677A BR112017027677A BR112017027677A2 BR 112017027677 A2 BR112017027677 A2 BR 112017027677A2 BR 112017027677 A BR112017027677 A BR 112017027677A BR 112017027677 A BR112017027677 A BR 112017027677A BR 112017027677 A2 BR112017027677 A2 BR 112017027677A2
Authority
BR
Brazil
Prior art keywords
antibody
peptide
gene
kit
vector
Prior art date
Application number
BR112017027677A
Other languages
English (en)
Inventor
Spits Hergen
Aletta Gillissen Marijn
Kedde Martijn
Deborah Hazenberg Mette
Maria Wilhelmina Van Helden Paula
POS Wouter
Original Assignee
Aimm Therapeutics Bv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aimm Therapeutics Bv filed Critical Aimm Therapeutics Bv
Publication of BR112017027677A2 publication Critical patent/BR112017027677A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70596—Molecules with a "CD"-designation not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57426—Specifically defined cancers leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/734—Complement-dependent cytotoxicity [CDC]
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/70596—Molecules with a "CD"-designation not provided for elsewhere in G01N2333/705

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Cell Biology (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Oncology (AREA)
  • General Physics & Mathematics (AREA)
  • Hospice & Palliative Care (AREA)
  • Food Science & Technology (AREA)
  • Analytical Chemistry (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicinal Preparation (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)

Abstract

a presente invenção provê compostos novos compreendendo um antígeno de células lma e usos do mesmo.
BR112017027677A 2015-06-24 2016-06-24 peptídeo, composto, mólecula de ácido nucleico, vetor, uso de um peptídeo, anticorpo, composição imunogênica, kit, métodos para determinar se um indivíduo tem lma e para produzir uma célula imune e/ou anticorpo, veículo de dispensação de gene, e, célula hospedeira BR112017027677A2 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP15173662 2015-06-24
EP16150621 2016-01-08
PCT/NL2016/050449 WO2016209079A1 (en) 2015-06-24 2016-06-24 Aml antigens and uses thereof

Publications (1)

Publication Number Publication Date
BR112017027677A2 true BR112017027677A2 (pt) 2018-08-28

Family

ID=56567655

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112017027677A BR112017027677A2 (pt) 2015-06-24 2016-06-24 peptídeo, composto, mólecula de ácido nucleico, vetor, uso de um peptídeo, anticorpo, composição imunogênica, kit, métodos para determinar se um indivíduo tem lma e para produzir uma célula imune e/ou anticorpo, veículo de dispensação de gene, e, célula hospedeira

Country Status (14)

Country Link
US (2) US11524989B2 (pt)
EP (1) EP3313870B1 (pt)
JP (2) JP7010704B2 (pt)
KR (1) KR20180118101A (pt)
CN (1) CN107810191B (pt)
AU (2) AU2016281424B2 (pt)
BR (1) BR112017027677A2 (pt)
CA (1) CA2989551A1 (pt)
DK (1) DK3313870T3 (pt)
EA (1) EA201792492A1 (pt)
HK (1) HK1247934A1 (pt)
MX (1) MX2017016258A (pt)
TW (1) TWI751110B (pt)
WO (1) WO2016209079A1 (pt)

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7399847B1 (en) 1996-11-25 2008-07-15 The General Hospital Corporation Nucleic acids encoding artificial P-selectin ligands
EP1452868A2 (en) * 2003-02-27 2004-09-01 Pepscan Systems B.V. Method for selecting a candidate drug compound
KR100738401B1 (ko) * 2005-05-11 2007-07-11 다이노나(주) 급성백혈병- 및 림프모구 림프종 특이 ｃｄ43의항원결정부위 및 이의 용도
US7622560B2 (en) 2005-05-11 2009-11-24 Dinona Inc. Monoclonal antibody specific for CD43 epitope
BRPI0611044A2 (pt) * 2005-05-11 2010-12-14 Dinona Inc polipeptÍdio isolado, anticorpos ou respectivos fragmentos, cÉlula, mÉtodos de diagnàstico e de tratamento da leucemia aguda, da leucemia crânica com crise de blastos e do linfoma linfoblÁstico, composiÇÕes farmacÊuticas e kits de diagnàstico
US9005974B2 (en) 2005-12-09 2015-04-14 Academish Medisch Centrum Bij De Universiteit Van Amsterdam Means and methods for influencing the stability of cells
ES2444465T5 (es) 2005-12-09 2023-11-30 Academisch Medisch Centrum Bij De Univ Van Amsterdam Medios y procedimientos para influenciar la estabilidad de las células productoras de anticuerpos
DK2044120T3 (da) 2006-06-07 2019-04-15 Bioalliance Cv Antistoffer, der genkender en kulhydratholdig epitop på cd-43 og cea eksprimeret på cancerceller, og fremgangsmåder til anvendelse deraf
EP1997830A1 (en) 2007-06-01 2008-12-03 AIMM Therapeutics B.V. RSV specific binding molecules and means for producing them
NZ585959A (en) * 2007-12-18 2012-09-28 Bioalliance Cv Antibodies recognizing a carbohydrate containing epitope on cd-43 and cea expressed on cancer cells and methods using same
AU2012346669B2 (en) 2011-12-02 2017-08-31 Kling Biotherapeutics B.V. Influenza A virus specific antibodies
EP3572425A1 (en) * 2013-12-17 2019-11-27 AIMM Therapeutics B.V. Means and methods for counteracting myeloproliferative or lymphoproliferative disorders

Also Published As

Publication number Publication date
EP3313870B1 (en) 2020-06-03
EP3313870A1 (en) 2018-05-02
CN107810191A (zh) 2018-03-16
US11524989B2 (en) 2022-12-13
AU2016281424B2 (en) 2020-12-24
NZ738289A (en) 2021-08-27
DK3313870T3 (da) 2020-08-31
AU2020294288B2 (en) 2022-05-05
US20180170998A1 (en) 2018-06-21
CN107810191B (zh) 2023-06-13
JP2022000038A (ja) 2022-01-04
TW201718631A (zh) 2017-06-01
CA2989551A1 (en) 2016-12-29
AU2016281424A1 (en) 2018-01-04
MX2017016258A (es) 2018-04-20
TWI751110B (zh) 2022-01-01
JP7010704B2 (ja) 2022-02-10
EA201792492A1 (ru) 2018-07-31
AU2020294288A1 (en) 2021-01-28
US20230235018A1 (en) 2023-07-27
JP2018520670A (ja) 2018-08-02
HK1247934A1 (zh) 2018-10-05
WO2016209079A1 (en) 2016-12-29
AU2020294288B9 (en) 2022-05-19
KR20180118101A (ko) 2018-10-30

Similar Documents

Publication Publication Date Title
BR112017009728A2 (pt) anticorpos isolados, ácido nucleico isolado, vetor, célula hospedeira, método para produzir o anticorpo, composição, usos de um anticorpo e métodos de tratamento de um distúrbio
BR112017025564B8 (pt) Anticorpos anti-ctla-4 e métodos de uso dos mesmos
BR112018074325A2 (pt) anticorpo para ligação a receptor de interleucina 4
BR112019007369A2 (pt) anticorpos anti-lag-3 e métodos de uso dos mesmos
CY1123932T1 (el) Δομες πολυειδικου αντισωματος
CY1123274T1 (el) Αντισωματα εναντι-οχ40 και χρησεις αυτων
TWI799368B (zh) 抗ｔｌ１ａ抗原結合蛋白及相關核酸、表現載體、宿主細胞、醫藥組合物、方法及用途
BR112016013347A8 (pt) anticorpo monoclonal humano neutralizante anti-il-33,composição farmacêutica,inibidor da expressão de citocinas,epitopo,molécula de ácido nucleico,vetor,célula hospedeira,método de produção e uso dos mesmos.
BR112019003129A2 (pt) composição compreendendo um domínio de ligação a antígeno que se liga a tigit humano, composição de ácido nucleico e de vetor de expressão, célula hospedeira, e, métodos para preparação de um anticorpo anti-tigit e para tratar cancer.
WO2016130704A3 (en) Methods and compositions for analyzing cellular components
BR112017015567A2 (pt) proteína gl de citomegalovírus recombinante ou fragmento de formação de complexo da mesma, complexo de citomegalovírus, ácido nucleico isolado, célula hospedeira, e, composição imunogênica
BR112017011326A2 (pt) anticorpo, ácido nucleico, vetor, célula hospedeira, método para produzir o anticorpo, imunoconjugado, composição farmacêutica, usos do anticorpo, métodos para tratar ou retardar a progressão de distúrbio proliferativo celular e para intensificar a função imune
PE20210107A1 (es) Anticuerpos anti-cd3 y metodos de uso
PE20180480A1 (es) Anticuerpos de factor xi y metodos de uso
BR112017014031A2 (pt) n-oligossacaril-transferase recombinante, mutante de n-oligossacaril-transferase recombinante, ácido nucleico, célula hospedeira, e, método para produção de um bioconjugado.
BR112016010706A2 (pt) anticorpo biespecífico, composição farmacêutica, uso do anticorpo biespecífico, sequência de ácido nucleico, vetor de expressão, célula hospedeira e método de produção de um anticorpo
EA201490815A1 (ru) Составы этанерцепта, стабилизированные с помощью аминокислот
WO2018081592A3 (en) Compositions and methods for the production of compounds
BR112017009021A2 (pt) formulação farmacêutica de anticorpo anti-tnfa
EA201792080A1 (ru) Гуманизированные анти-c1s антитела и способы их применения
CL2020000937A1 (es) Anticuerpo multiespecífico.
BR112018001202A2 (pt) anticorpo monoclonal, ácido nucleico, vetor, célula hospedeira, composição farmacêutica e método
BR112017006598A2 (pt) anticorpo de repetições antidipeptídeo derivado de ser humano (dprs)
BR112016008477A2 (pt) Corpos, ácido nucleico, célula hospedeira, método de produção de um anticorpo, imunoconjugado, formulação farmacêutica e usos do anticorpo
EA201792289A1 (ru) Способы обнаружения агглютинации и композиции для их осуществления

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]

Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS.

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B25G Requested change of headquarter approved

Owner name: AIMM THERAPEUTICS B.V. (NL)

B25A Requested transfer of rights approved

Owner name: KLING BIOTHERAPEUTICS B.V. (NL)